CN107670011A - 一种降血脂的中西药制剂及其制备方法 - Google Patents
一种降血脂的中西药制剂及其制备方法 Download PDFInfo
- Publication number
- CN107670011A CN107670011A CN201711093420.9A CN201711093420A CN107670011A CN 107670011 A CN107670011 A CN 107670011A CN 201711093420 A CN201711093420 A CN 201711093420A CN 107670011 A CN107670011 A CN 107670011A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese
- western medicine
- reducing blood
- blood lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 35
- 210000004369 blood Anatomy 0.000 title claims abstract description 35
- 150000002632 lipids Chemical class 0.000 title claims abstract description 31
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 42
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 22
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 22
- 239000011570 nicotinamide Substances 0.000 claims abstract description 22
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 22
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims abstract description 22
- 229960002855 simvastatin Drugs 0.000 claims abstract description 22
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims abstract description 21
- 229960004601 aliskiren Drugs 0.000 claims abstract description 21
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 21
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 21
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 21
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 20
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 20
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 20
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 20
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 20
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 20
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 20
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 20
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 20
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 20
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 20
- 240000008916 Oenothera biennis Species 0.000 claims abstract description 20
- 235000004496 Oenothera biennis Nutrition 0.000 claims abstract description 20
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 20
- 229940045761 evening primrose extract Drugs 0.000 claims abstract description 20
- 235000008524 evening primrose extract Nutrition 0.000 claims abstract description 20
- 235000008397 ginger Nutrition 0.000 claims abstract description 20
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 19
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 19
- 150000004676 glycans Chemical class 0.000 claims abstract description 19
- 239000004006 olive oil Substances 0.000 claims abstract description 19
- 235000008390 olive oil Nutrition 0.000 claims abstract description 19
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 19
- 239000005017 polysaccharide Substances 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 13
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 20
- 229930064664 L-arginine Natural products 0.000 claims description 20
- 235000014852 L-arginine Nutrition 0.000 claims description 20
- 241001092040 Crataegus Species 0.000 claims description 19
- 241000219051 Fagopyrum Species 0.000 claims description 19
- 241000234314 Zingiber Species 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 3
- 240000007817 Olea europaea Species 0.000 claims 1
- 241000219780 Pueraria Species 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 230000007102 metabolic function Effects 0.000 abstract description 3
- 239000004475 Arginine Substances 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 240000008620 Fagopyrum esculentum Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于医药技术领域，具体公开了一种降血脂的中西药制剂及其制备方法，按重量份数计，由以下原料组成：辛伐他汀1‑3份、烟酸2‑10份、阿利克仑2‑4份、烟酰胺2‑5份、L‑精氨酸0.1‑0.5份、大枣多糖1‑5份、橄榄油1‑6份、番泻叶30‑50份、山楂20‑30份、月见草30‑50份、生姜5‑10份、苦荞5‑10份和和葛根5‑10份。本发明降血脂的中西药制剂经合理配比制成，具有药物协同作用，不仅可以改善人体代谢机能，加快新陈代谢，还能够使降脂效果进一步增强。
Description
技术领域
本发明属于医药技术领域，具体涉及一种降血脂的中西药制剂及其制备方法。
背景技术
大量研究资料表明，高血脂是脑卒中、冠心病、心肌梗死、心脏猝死等发生的重要因素，另外高血脂症也是促进高血压、糖耐量异常、糖尿病等的危险因素，高血脂症还可以导致脂肪肝、肝硬化、胆石症、胰腺炎、眼底出血、失明、周围血管疾病、跛行、高尿酸血症等疾病。高血脂症是中老年的常见病和多发病，随着人们生活水平的提高和生活习惯的改变，该病的发病率明显增加，发病的年龄也有所提前，严重危害到了人类生命健康。目前，西药调节血脂虽有肯定的疗效，担忧不同程度的副作用，且作用的靶点单一。目前认为调节血脂最有效的西药是他汀类，但费用较高，且有肝脏和肌肉毒性副作用。目前降低高血脂症的中药也有很多，但疗效极差。
所以研究开发中西医结合药物既能较好降低高脂血症又能减少不良反应，降低毒性。产品有其巨大社会价值和经济价值。
发明内容
为了解决上述问题，本发明提供一种降血脂中西药制剂及其制备方法，本药物结合中西医药学理论，合理配比，组成本发明一种降血脂的中西药制剂，调节脂肪代谢、保护和提高脏器功能、改善身体机能。
本发明解决上述技术问题的技术方案如下：一种降血脂的中西药制剂，按重量份数计，由以下原料组成：辛伐他汀1-3份、烟酸2-10份、阿利克仑2-4份、烟酰胺2-5份、L-精氨酸0.1-0.5份、大枣多糖1-5份、橄榄油1-6份、番泻叶30-50份、山楂20-30份、月见草30-50份、生姜5-10份、苦荞5-10份和葛根5-10份。
在上述技术方案的基础上，本发明还可以做如下改进。
优选的，一种降血脂的中西药制剂，按重量份数计，由以下原料组成：辛伐他汀1份、烟酸2份、阿利克仑4份、烟酰胺2份、L-精氨酸0.5份、大枣多糖1份、橄榄油6份、番泻叶30份、山楂20份、月见草50份、生姜5份、苦荞5份和葛根5份。
优选的，一种降血脂的中西药制剂，按重量份数计，由以下原料组成：辛伐他汀3份、烟酸10份、阿利克仑2份、烟酰胺5份、L-精氨酸0.3份、大枣多糖5份、橄榄油5份、番泻叶50份、山楂20份、月见草50份、生姜10份、苦荞10份和葛根10份。
优选的，一种降血脂的中西药制剂，按重量份数计，由以下原料组成：辛伐他汀2份、烟酸5份、阿利克仑3份、烟酰胺3份、L-精氨酸0.3份、大枣多糖3份、橄榄油6份、番泻叶40份、山楂25份、月见草40份、生姜8份、苦荞8份和葛根8份。
本发明还提供一种降血脂的中西药制剂的制备方法，包括以下步骤：
步骤1：取辛伐他汀1-3份、烟酸2-10份、阿利克仑2-4份、烟酰胺2-5份、L-精氨酸0.1-0.5份、大枣多糖1-5份、橄榄油1-6份、番泻叶30-50份、山楂20-30份、月见草30-50份、生姜5-10份、苦荞5-10份和葛根5-10份；
步骤2：将番泻叶、山楂、月见草、生姜、苦荞和葛根混合，加药材重量5-10倍、体积分数为50-60％的乙醇溶液，升温至40-50℃，浸泡2-3小时，继续升温至60-80℃，浸泡20-60分钟，煎煮50-100分钟，过滤，干燥至含水量为20-40wt％得到药液；
步骤3：将辛伐他汀、烟酸、阿利克仑、烟酰胺、L-精氨酸、大枣多糖和橄榄油混合均匀，加入步骤3所述药液进行混合均匀，压片，包衣得到降血脂的中西药制剂。
与现有技术相比，本发明的有益效果是：
本发明中西结合，不仅降血脂效果显著，且几乎无不良反应，费用低，工艺简单；其中番泻叶、山楂、月见草、生姜、苦荞和葛根不仅能有效降低血脂还能够有效派出积累在肠道内的毒素，调节脂质代谢，降血脂、降血压，与辛伐他汀、泛酸钙、烟酰胺、L-精氨酸合用，具有协同作用，不仅可以改善人体代谢机能，加快新陈代谢，还能够使降脂效果进一步增强。
具体实施方式
以下对本发明的原理和特征进行描述，所举实例只用于解释本发明，并非用于限定本发明的范围。
实施例1
一种降血脂的中西药制剂的制备方法，包括以下步骤：
步骤1：取以下原料：辛伐他汀1g、烟酸2g、阿利克仑4g、烟酰胺2g、L-精氨酸0.5g、大枣多糖1g、橄榄油6g、番泻叶30g、山楂20g、月见草50g、生姜5g、苦荞5g和葛根5g。
步骤2：将番泻叶、山楂、月见草、生姜、苦荞和葛根混合，加药材重量10倍、体积分数为50％的乙醇溶液，升温至50℃，浸泡2小时，继续升温至80℃，浸泡20分钟，煎煮50分钟，过滤，干燥至含水量为20-40wt％得到药液；
步骤3：将辛伐他汀、烟酸、阿利克仑、烟酰胺、L-精氨酸、大枣多糖和橄榄油混合均匀，加入步骤3所述药液进行混合均匀，压片，规格1.5g/片，包衣得到降血脂的中西药制剂。
实施例2
一种降血脂的中西药制剂的制备方法，包括以下步骤：
步骤1：取以下原料：辛伐他汀3g、烟酸10g、阿利克仑2g、烟酰胺5g、L-精氨酸0.3g、大枣多糖5g、橄榄油5g、番泻叶50g、山楂20g、月见草50g、生姜10g、苦荞10g和葛根10g。
步骤2：将番泻叶、山楂、月见草、生姜、苦荞和葛根混合，加药材重量8倍、体积分数为60％的乙醇溶液，升温至40℃，浸泡3小时，继续升温至70℃，浸泡30分钟，煎煮70分钟，过滤，干燥至含水量为20-40wt％得到药液；
步骤3：将辛伐他汀、烟酸、阿利克仑、烟酰胺、L-精氨酸、大枣多糖和橄榄油混合均匀，加入步骤3所述药液进行混合均匀，压片，规格1.5g/片，包衣得到降血脂的中西药制剂。
实施例3
一种降血脂的复方制剂的制备方法，包括以下步骤：
步骤1：取以下原料：辛伐他汀2g、烟酸5g、阿利克仑3g、烟酰胺3g、L-精氨酸0.3g、大枣多糖3g、橄榄油6g、番泻叶40g、山楂25g、月见草40g、生姜8g、苦荞8g和葛根8g。
步骤2：将番泻叶、山楂、月见草、生姜、苦荞和葛根混合，加药材重量5倍、体积分数为50％的乙醇溶液，升温至40℃，浸泡3小时，继续升温至60℃，浸泡60分钟，煎煮50分钟，过滤，干燥至含水量为20-40wt％得到药液；
步骤3：将辛伐他汀、烟酸、阿利克仑、烟酰胺、L-精氨酸、大枣多糖和橄榄油混合均匀，加入步骤3所述药液进行混合均匀，压片，规格1.5g/片，包衣得到降血脂的中西药制剂。
对比例：
一种降血脂的复方制剂的制备方法，包括以下步骤：
步骤1：取以下原料：辛伐他汀1g、烟酸2g、阿利克仑4g、烟酰胺2g和L-精氨酸0.5g、。
步骤2：辛伐他汀、烟酸、阿利克仑、烟酰胺和L-精氨酸0.5份混合均匀，压片，规格1.5g/片，包衣得到降血脂的西药制剂。
将上述实施例1制备所得的复方制剂进行如下药效学实验：
1、病例选择：
选择确诊的高血脂患者200例临床观察，患者甘油三酯的水平均高于2.26mmol/L，胆固醇含量均高于5.17mmol/L，病人随机分成治疗组和对照组，治疗组100例，男性55例，女性45例，年龄在35-85岁，平均年龄47.5岁，患病时间平均为7.1年。对照组100例，其中男性53例，女性47例，年龄在32-78岁，平均年龄46.8岁，患病时间平均为7.2年。
治疗组和对照组两组病例的病程、症状轻重程度基本一致，无显著差异，具有可比性。
2、药物选择：
治疗组服用本发明实施例1制备的中西药制剂，每日1次，每次1粒，温开水送服，10天为一个疗程，服用2个疗程。
对照组服用本发明对比例制备的中药制剂，每日1次，每次1粒，温开水送服，10天为一个疗程，服用2个疗程。
3、疗效判定：
(1)治愈：用药后，胆固醇和甘油三酯均处于正常值范围，胆固醇含量低于5.17mmol/L，甘油三酯含量低于2.26mmol/L。
(2)显效：用药后，血脂水平有所下降，但为未下降至正常水平。
(3)无效：用药后患者血脂水平无任何下降趋势。
4、结果说明
治疗组，治愈78例，显效20例，无效2例。
对照组，治愈53例，显效22例，无效25例。
以上结果表明，治疗组的治愈率远大于对照组，这也是本发明的降血脂的复方制剂的优势所在，本发明的中西药制剂具有协同作用，不仅可以改善人体代谢机能，加快新陈代谢，还能够使降脂效果进一步增强。
Claims (5)
1.一种降血脂的中西药制剂，其特征在于，按重量份数计，由以下原料组成：辛伐他汀1-3份、烟酸2-10份、阿利克仑2-4份、烟酰胺2-5份、L-精氨酸0.1-0.5份、大枣多糖1-5份、橄榄油1-6份、番泻叶30-50份、山楂20-30份、月见草30-50份、生姜5-10份、苦荞5-10份和和葛根5-10份。
2.根据权利要求1所述的一种降血脂的中西药制剂，其特征在于，按重量份数计，由以下原料组成：辛伐他汀1份、烟酸2份、阿利克仑4份、烟酰胺2份、L-精氨酸0.5份、大枣多糖1份、橄榄油6份、番泻叶30份、山楂20份、月见草50份、生姜5份、苦荞5份和葛根5份。
3.根据权利要求1所述的一种降血脂的中西药制剂，其特征在于，按重量份数计，由以下原料组成：辛伐他汀3份、烟酸10份、阿利克仑2份、烟酰胺5份、L-精氨酸0.3份、大枣多糖5份、橄榄油5份、番泻叶50份、山楂20份、月见草50份、生姜10份、苦荞10份和葛根10份。
4.根据权利要求1所述的一种降血脂的中西药制剂，其特征在于，按重量份数计，由以下原料组成：辛伐他汀2份、烟酸5份、阿利克仑3份、烟酰胺3份、L-精氨酸0.3份、大枣多糖3份、橄榄油6份、番泻叶40份、山楂25份、月见草40份、生姜8份、苦荞8份和葛根8份。
5.一种如权利要求1任一所述的降血脂的中西药制剂，其特征在于，包括如下步骤：
步骤1：取辛伐他汀1-3份、烟酸2-10份、阿利克仑2-4份、烟酰胺2-5份、L-精氨酸0.1-0.5份、大枣多糖1-5份、橄榄油1-6份、番泻叶30-50份、山楂20-30份、月见草30-50份、生姜5-10份、苦荞5-10份和葛根5-10份；
步骤2：将番泻叶、山楂、月见草、生姜、苦荞和葛根混合，加药材重量5-10倍、体积分数为50-60％的乙醇溶液，升温至40-50℃，浸泡2-3小时，继续升温至60-80℃，浸泡20-60分钟，煎煮50-100分钟，过滤，干燥至含水量为20-40wt％得到药液；
步骤3：将辛伐他汀、烟酸、阿利克仑、烟酰胺、L-精氨酸、大枣多糖和橄榄油混合均匀，加入步骤3所述药液进行混合均匀，压片，包衣得到降血脂的中西药制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711093420.9A CN107670011A (zh) | 2017-11-08 | 2017-11-08 | 一种降血脂的中西药制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711093420.9A CN107670011A (zh) | 2017-11-08 | 2017-11-08 | 一种降血脂的中西药制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107670011A true CN107670011A (zh) | 2018-02-09 |
Family
ID=61146843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711093420.9A Withdrawn CN107670011A (zh) | 2017-11-08 | 2017-11-08 | 一种降血脂的中西药制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107670011A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247345A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血脂组合物 |
| CN105616481A (zh) * | 2016-03-03 | 2016-06-01 | 广东福寿仙生物科技有限公司 | 一种降血脂中西药制剂及其制备方法 |
| CN106075343A (zh) * | 2016-07-14 | 2016-11-09 | 高文广 | 一种降血脂中西药制剂及其制备方法 |
-
2017
- 2017-11-08 CN CN201711093420.9A patent/CN107670011A/zh not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247345A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血脂组合物 |
| CN105616481A (zh) * | 2016-03-03 | 2016-06-01 | 广东福寿仙生物科技有限公司 | 一种降血脂中西药制剂及其制备方法 |
| CN106075343A (zh) * | 2016-07-14 | 2016-11-09 | 高文广 | 一种降血脂中西药制剂及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 黄锦荣: "辛伐他汀与洛伐他汀治疗高脂血症效果比较", 《中国校医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1895620A (zh) | 一种治疗冠心病的中药组合物 | |
| CN101108227A (zh) | 一种魔芋精粉胶囊 | |
| CN118105451A (zh) | 一种防治溃疡性结肠炎的药食同源组合物及其应用 | |
| CN110251591A (zh) | 一种辅助降血压降血糖的药物组合物及其制备方法和用途 | |
| CN102552734B (zh) | 一种治疗口腔溃疡的漱口液 | |
| CN107670011A (zh) | 一种降血脂的中西药制剂及其制备方法 | |
| CN103479895A (zh) | 一种舒心清脑中药组合物 | |
| CN101850031B (zh) | 葛根异黄酮胶囊 | |
| CN101195006B (zh) | 一种治疗风火牙痛的外搽药物 | |
| CN1141125C (zh) | 具有降糖作用的中药组合物 | |
| CN107693598A (zh) | 一种降血脂的复方制剂及其制备方法 | |
| CN102772505A (zh) | 一种治疗脓疱疮的油剂药物 | |
| CN103505507A (zh) | 一种含有灵芝的中药组合物及制备方法 | |
| CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 | |
| CN109865131B (zh) | 一种调理心脑血管功能的螺旋藻制剂及其制备方法和应用 | |
| CN102552481A (zh) | 一种通络降压中药组合物及其制备方法 | |
| CN102204956A (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
| CN1879721A (zh) | 一种治疗痹症的复方胶囊 | |
| CN101991829A (zh) | 一种治疗胃病的药物 | |
| CN1861072A (zh) | 苹果多酚作为制备治疗支气管炎或哮喘的药物 | |
| CN1883553A (zh) | 一种用于防治冠心病、心绞痛的药物组合物及制备方法 | |
| CN103610965B (zh) | 一种治疗心血瘀阻型胸痹的药剂 | |
| CN105311341A (zh) | 一种同步治疗和预防“4高”的内服中药制剂 | |
| CN103550373B (zh) | 一种治疗牙龈炎的药剂 | |
| CN1057008C (zh) | 茶色素在制备治疗病毒性心肌炎药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180209 |